Grintuss Adult Tablets
Soothes coughs, protecting the mucosa
The entire Products section of this website is an English translation of the official Italian Aboca website. It contains the list of Aboca products marketed in Italy and their related details. Please be aware that the information contained in each product data sheet is in accordance with Italian law only and may not reflect the legislation, regulations or other requirements applicable in your country. If you would like to see the leaflets for the countries that are supported but that do not have a dedicated site, please click here.
Learn more
Grintuss is made with honey and molecular complexes that protect and soothe the upper airways. It soothes dry coughs by reducing the irritation of the mucosa and helps hydrate and eliminate mucus in case of chesty coughs.
Grintuss Adult tablets are made using innovative extraction and manufacturing processes that achieve greater concentrations of the polysaccharide, resinoid and flavonoid fractions, which provide the mucoadhesive action and protect the mucosa.
The honey included in the formulation contributes to these properties and gives the tablets their pleasant flavour.
Grintuss is made with ingredients obtained through organic farming and is gluten free.
INSTRUCTIONS
Grintuss Adult tablets are indicated for the treatment of either dry or chesty coughs in adults and in children aged 12 and up.
HOW IT WORKS
Grintuss Adult tablets protect the mucosa, soothe irritation and help hydrate and remove mucus through the following mechanisms:
- Barrier Effect: forms a protective film that adheres to the mucosa and protects it against contact with irritants
- Mucoregulatory Action: helps hydrate and eliminate mucus
- Lubricating Action: reduces the friction in the pharynx that triggers coughing
Grintuss modulates the cough without suppressing it, thereby respecting the important role of coughing as a defence of the upper airways.
Read the warnings and instructions for use carefully.
Instructions for use
Take 1 tablet, 2 to 4 times per day, allowing it to dissolve slowly in your mouth.
Composition
COMPOSITION FUNCTIONAL INGREDIENTS:
• Honey*;
• Molecular complex with Resins, Polysaccharides and Flavonoids from Grindelia*, Ribwort plantain* and Helichrysum* (Poliresin®);
Titrated in polysaccharides (molecular weight > 20,000 daltons) ≥ 20%
Also contains: Cane sugar*; Gum arabic; Natural Peppermint and Eucalyptus scent; Peppermint and Eucalyptus essential oils
*Ingredient from Organic Farming
Warnings
Do not use in case of individual hypersensitivity or allergies to one or more components. In the event that symptoms don't improve, seek medical advice. Store at room temperature, away from heat sources and protected from light.
Keep out of reach of children.
Scientific evidence
CLINICAL TRIALS
THE SAFETY AND EFFECTIVENESS OF THE INNOVATIVE, NON-PHARMACOLOGICAL APPROACH TO TREATING BOTH ACUTE AND PERSISTENT COUGHS WITH GRINTUSS HAS BEEN CONFIRMED BY TWO MULTICENTRE CLINICAL TRIALS.
Multicentre clinical trial; randomised, single-blind study vs carbocysteine
Multicentre clinical trial; randomised, double-blind study vs placebo
1. CLINICAL TRIAL FOR ACUTE COUGHS
Evidence
Efficacy and tolerability of polysaccharide-resin-honey based cough syrup as compared to carbocysteine syrup for children with colds: a randomized, single-blinded multicenter study
Cohen, H.A., Hoshen, M., Gur, S. et al. World J Pediatr (2016). doi:10.1007/s12519-016-0048-4
Characteristics of the trial
- CLINICAL: conducted on 141 children between 2 and 5 years of age with a cough of less than 7 days duration related to an upper respiratory tract infection (URTI).
- MULTICENTRE: conducted at 4 Outpatient Paediatric Community Clinics.
- RANDOMISED, SINGLE-BLIND, COMPARED WITH CARBOCYSTEINE: the children were randomly assigned to the group treated with Grintuss or the group treated with Carbocysteine (Mucolit CTS Ltd). The Physician and the Coordinators of the study did not know which treatment the children were receiving.
Results of the study
SPEED OF ACTION: GRINTUSS IS EFFECTIVE AGAINST ACUTE COUGHS FROM THE FIRST ADMINISTRATION
The group treated with Grintuss showed a statistically significant improvement in the overall cough score compared to the group treated with Carbocysteine.
show image
The improved score noted for Grintuss, as compared to Carbocysteine, was also statistically significant for each of the parameters that make up the combined score.
show image
The excellent results obtained in the cough parameters provided above were also borne out in the parameters related to the quality of sleep of the children and parents, which improved significantly for the Grintuss group.
AN IMPROVEMENT THAT CONTINUED FOR THE ENTIRE DURATION OF THE TREATMENT
The study indicated the effectiveness of the product for a period of 4 days, which represents the average duration of an acute cough. The data shows that Grintuss was significantly more effective in improving all parameters both for daytime and night-time coughs.
show image
Tolerability
Both treatments demonstrated a good safety profile.
In final analysis, Grintuss demonstrated a more rapid and significant improvement of the cough compared to carbocysteine across all the clinical symptoms of a cough, starting from the first night and continuing for the entire duration of the treatment.
2. CLINICAL TRIAL ON PERSISTENT COUGHS: RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL WITH PLACEBO
show image
The safety and effectiveness of the innovative non-pharmacological mode of action used to treat coughs, including persistent coughs, with Grintuss was confirmed by a clinical trial published in the prestigious “Italian Journal of Pediatrics”. A persistent cough is a common and problematic condition: it is estimated that coughs that persist for more than 10 days occur in 50% of children, and the condition poses a risk of chronic illness even in the absence of a specific organic disease.
show image
Grintuss, thanks to its innovative mode of action, forms a protective barrier between irritants and the mucosa, reducing the inflammation that underlies both the initial trigger and the persistence of a cough. A persistent cough is associated with the sensitization of the mucosa, which occurs as a result of an inflammatory process activated by external irritants.
Evidence
This clinical trial was conducted at two primary hospital centres, Servizio di Allergo-Patologia Azienda Ospedaliero Universitaria Santa Maria della Misericordia di Udine (Dr. Mario Canciani) and Dipartimento Materno Infantile, Struttura di Pediatria I.R.C.C.S Policlinico San Matteo di Pavia (Prof. Gianluigi Marseglia).
Sample
show image
The study recruited 102 children ages 3 to 6 with a cough that persisted for at least 7 days and no more than 3 weeks, who had not received any other treatment for the cough (Authorisation by the Ethical Committee on 09/03/2010).
Exclusion Criteria:
- Treatment with antibiotics (even if administered prophylactically)
- Treatment with systemic corticosteroids (including aerosol)
- Treatment with immune system modulators or regulators in the previous month
- Congenital or acquired immunodeficiency
- Presence of chronic diseases (pulmonary disease, kidney failure, heart disease) or bacterial disease in progress (pneumonia or sepsis)
- Suspected or diagnosed asthma
Objective
The primary objective of the study was to evaluate the clinical efficacy of Grintuss evaluating changes in the daytime and night-time cough score at 4 and 8 days after administration of the product.
Results of the study
show image
Grintuss reduces the frequency of night-time waking: Improving a night-time cough guarantees restful sleep and improves the quality of life of the child and of the family.
show image
Grintuss improves a persistent cough right from the first days: The improvement spares parents, who are worried about the duration of the ailment, from resorting to other, at times inappropriate, treatments.
GRINTUSS PROVED PARTICULARLY EFFECTIVE ON MORE INTENSE COUGHS AS EARLY AS THE 4TH DAY OF TREATMENT
show image
Over the course of the clinical trials adverse events correlated with the administration of the product were not noted.
In both studies Grintuss proved to be SAFE and WELL TOLERATED, confirming the efficacy of the innovative mechanism of action provided by the POLIRESIN® natural molecular complex, which led to Grintuss becoming the reference product for treating both acute and persistent coughs.
The results of these clinical studies support the evidence that Grintuss Pediatric syrup is of interest for its efficacy and safety when treating either acute or persistent coughs. The mechanical barrier reduces contact with external microorganisms and irritants and helps the mucosa regain its physiological function.
The usefulness of the innovative action of Grintuss in the treatment of persistent coughs was the topic of a patent request (request no. RM2013A000716).
EFFICACY TEST
1. BARRIER EFFECT TEST
The test conducted with the Syrup for adults and the Syrups for children confirmed that the formulation is able to create a protective film that limits contact between cells and irritants.
show image
2. MUCOADHESION TEST
The test conducted with Grintuss syrup for adults and children showed that the syrup retains mucoadhesive properties at dilutions that mimic the normal dilution of the product after application and the resistance of the mucoadhesive properties to washing, in conditions that mimic continuous deglutition.
show image
3. TEST FOR THE HEALING OF MINOR INJURIES OF THE mucosa
The test conducted with the Syrup for adults showed that the product favours the healing of the injury at all concentrations tested.
SAFETY STUDIES
BIOCOMPATIBILITY TEST
This test was conducted on all Medical Devices in the Grintuss line. The results of these tests back the statement that Grintuss Adult syrup, Grintuss Pediatric syrup and Grintuss Adult tablets do not have an irritant or sensitising effect.
